Enveric Biosciences Inc (ENVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,856 | -11,034 | -4,678 | -18,471 | -9,793 |
| Depreciation Amortization | 324 | 228 | 113 | 7,889 | 345 |
| Other Working Capital | -381 | -624 | -923 | -218 | -956 |
| Other Operating Activity | 1,570 | 1,827 | 350 | -6,347 | -3,280 |
| Operating Cash Flow | $-12,343 | $-9,603 | $-5,137 | $-17,147 | $-13,685 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 12 | 12 | -5 | -584 | -578 |
| Investing Cash Flow | $12 | $12 | $-5 | $-584 | $-578 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | N/A | 17,222 | 17,222 |
| Other Financing Activity | -1,157 | -1,052 | 0 | 958 | 958 |
| Financing Cash Flow | $-1,157 | $-1,052 | $N/A | $18,180 | $18,180 |
| Exchange Rate Effect | 31 | 1 | -20 | -81 | -73 |
| Beginning Cash Position | 17,724 | 17,724 | 17,724 | 17,356 | 17,356 |
| End Cash Position | 4,267 | 7,081 | 12,562 | 17,724 | 21,201 |
| Net Cash Flow | $-13,457 | $-10,643 | $-5,162 | $368 | $3,845 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,343 | -9,603 | -5,137 | -17,147 | -13,685 |
| Capital Expenditure | -5 | -5 | -5 | -584 | -578 |
| Free Cash Flow | -12,349 | -9,608 | -5,142 | -17,731 | -14,263 |